Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro

Journal of General Virology

Volumn 88, Issue 12, 2007, Pages 3270-3274

  Bonvin, Marianne ^a   Greeve, Jobst ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; CYTIDINE DEAMINASE; PROTEIN APOBEC3B; UNCLASSIFIED DRUG; VIRUS DNA;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEAMINATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION;

CELL LINE, TUMOR; CYTIDINE DEAMINASE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 36749080330     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83149-0     Document Type: Article

References (30)

1. Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S. J. & Malim, M. H. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14, 1392-1396.
2. Bogerd, H. P., Wiegand, H. L., Doehle, B. P., Lueders, K K. & Cullen, B. R. (2006a). APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 34, 89-95.
3. Bogerd, H. P., Wiegand, H. L., Hulme, A. E., Garcia-Perez, J. L., O'Shea, K. S., Moran, J. V. & Cullen, B. R. (2006b). Cellular inhibitors of long interspersed element 1 and A1u retrotransposition. Proc Natl Acad Sci U S A 103, 8780-8785.
4. Bogerd, H. P., Wiegand, H. L., Doehle, B. P. & Cullen, B. R. (2007). The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364, 486-493.
5. Bonvin, M., Achermann, F., Greeve, I., Stroka, D., Keogh, A., Inderbitzin, D., Candinas, D., Sommer, P., Wain-Hobson, S. & other authors (2006). Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364-1374.
6. + T cells. Nature 435, 108-114.
7. Chiu, Y.-L., Witkowska, H. E., Hall, S. C., Santiago, M., Soros, V. B., Esnault, C., Heidmann, T. & Greene, W. C. (2006). High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA 103, 15588-15593.
8. Esnault, C., Heidmann, O., Delebecque, F., Dewannieux M., Ribet, D., Hance, A. J., Heidmann, T. & Schwartz, O. (2005). APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433, 430-433.
9. Hache, G., Liddament, M. T. & Harris, R. S. (2005). The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem 280, 10920-10924.
10. Hakata, Y. & Landau, N. R. (2006). Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J Biol Chem 281, 36624-36631.
11. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S. & Malim, M. H. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809.
12. Hulme, A. E., Bogerd, H. P., Cullen, B. R. & Moran, J. V. (2007). Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390, 199-205.
13. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J. & Navaratnam, N. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296.
14. Liddament, M. T., Brown, W. L., Schumacher, A. J. & Harris, R. S. (2004). APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14, 1385-1391.
15. MacGinnitie, A. J., Anant, S. & Davidson, N. O. (1995). Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J Biol Chem 270, 14768-14775.
16. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L. & Trono, D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103.
17. Muckenfuss, H., Hamdorf, M., Held, U., Perkovic, M., Lower, J., Cichutek K., Flory, E., Schumann, G. G. & Munk, C. (2006). APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem 281, 22161-22172.
18. Navarro, F., Boliman, B., Chen, H., Konig, R., Yu, O., Chiles, K. & Landau, N. R. (2005). Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386.
19. Newman, E. N., Holmes, R. K., Craig, H. M., Klein, K. C., Lingappa, J. R., Malim, M. H. & Sheehy, A. M. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15, 166-170.
20. Nguyen, D. H., Gummuluru, S. & Hu, J. (2007). Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 81, 4465-4472.
21. Opi, S., Takeuchi, H., Kao, S., Khan, M. A., Miyagi, E., Golia-Gaur, R., Iwatani, Y., Levin, J. G. & Strebel, K. (2006). Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 80, 4673-4682.
22. Rosier, C., Kock, J., Kann, M., Malim, M. H., Blum, H. E., Baumert, T. F. & von Weizsacker, F. (2005). APOBEC-mediated interference with hepadnavirus production. Hepatology 42, 301-309.
23. Sasada, A., Takaori-Kondo, A., Shirakawa, K., Kobayashi, M., Abudu, A., Hishizawa, M., Imada, K., Tanaka, Y. & Uchiyama, T. (2005). APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2, 32.
24. Shindo, K., Takaori-Kondo, A., Kobayashi, M., Abudu, A., Fukunaga, K. & Uchiyama, T. (2003). The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 278, 44412-44416.
25. Stenglein, M. D. & Harris, R. S. (2006). APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 281, 16837-16841.
26. Suspene, R., Guetard, D., Henry, M., Sommer, P., Wain-Hobson, S. & artanian, J. P. (2005a). Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A 102, 8321-8326.
27. Suspene, R., Henry, M., Guillot, S., Wain-Hobson, S. & Vartanian, J. P. (2005b). Recovery of APOBEC3-edited human immunodeficiency virus G→A hypermutants by differential DNA denaturation PCR. J Gen Virol 86, 125-129.
28. Turelli, P., Mangeat, B., Jost S., Vianin, S. & Trono, D. (2004). Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829.
29. Wedekind, J. E., Dance, G. S., Sowden, M. P. & Smith, H. C. (2003). Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 19, 207-216.
30. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C. & Gao, L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98.